As a partner in the firm’s M&A group, Ro focuses on cutting-edge technology and biotech transactions, and he has guided his clients through high-stakes public and private mergers & acquisitions, venture capital financings, and securities offerings representing an aggregate value of more than $265 billion. He’s also one of the go-to M&A advisors for complex cross-border transactions in these areas. In recent years: Ro was the lead M&A partner advising Horizon Therapeutics on its $28.3 billion sale to Amgen, which was the largest healthcare deal of 2022 and the third-largest all-cash healthcare deal in history as of the announcement. Ro also led the team advising Japanese payments platform Paidy on its $2.7 billion sale to PayPal, which was named M&A Deal of the Year at the International Financial Law Review’s 2022 Asia-Pacific Awards.In addition, Ro is highly sought after by boards of directors and special committees for his expertise anddeep experience in activist defense, proxy contests, and corporate governance matters.Bar Admissions:CaliforniaNew York